UPDATE 1-Avid Bioservices to be taken private by GHO, Ampersand in $1.1 bln deal

Reuters

2024/11/07

(Adds details in paragraphs 2-5)

Nov 6 (Reuters) - Avid Bioservices said on Wednesday that it would be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in a deal valued at about $1.1 billion.

GHO and Ampersand have offered $12.50 per share in cash, representing a premium of 13.8% to Avid's last closing price.

The transaction is expected to close in the first quarter of 2025.

"In evaluating this transaction, our board considered a range of alternatives and determined that it provides our stockholders significant, immediate and certain cash value for their shares," Avid CEO Nick Green said.

Upon completion of the transaction, Avid common stock will no longer be listed on any public stock exchange. The company will continue to operate under the Avid name and brand.

Avid is a contract manufacturer that provides clinical and commercial manufacturing services to the biotechnology and biopharmaceutical industries.

(Reporting by Sneha S K in Bengaluru; Editing by Shailesh Kuber and Anil D'Silva)

((Sneha.SK@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2481964191"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2481964191\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2481964191?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-07 07:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481964191","market":"us","top_or_hot":-1,"title":"UPDATE 1-Avid Bioservices to be taken private by GHO, Ampersand in $1.1 bln deal","media":"Reuters","content":"<html><body><p>(Adds details in paragraphs 2-5)</p><p>      Nov 6 (Reuters) - Avid Bioservices    said on Wednesday that it would be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in a deal valued at about $1.1 billion.</p><p>   GHO and Ampersand have offered $12.50 per share in cash, representing a premium of 13.8% to Avid's last closing price. </p><p>       The transaction is expected to close in the first quarter of 2025.</p><p>       \"In evaluating this transaction, our board considered a range of alternatives and determined that it provides our stockholders significant, immediate and certain cash value for their shares,\" Avid CEO Nick Green said. </p><p>       Upon completion of the transaction, Avid common stock will no longer be listed on any public stock exchange. The company will continue to operate under the Avid name and brand.</p><p>       Avid is a contract manufacturer that provides clinical and commercial manufacturing services to the biotechnology and biopharmaceutical industries. </p><p> (Reporting by Sneha S K in Bengaluru; Editing by Shailesh Kuber and Anil D'Silva)</p><p>((Sneha.SK@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UPDATE 1-Avid Bioservices to be taken private by GHO, Ampersand in $1.1 bln deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUPDATE 1-Avid Bioservices to be taken private by GHO, Ampersand in $1.1 bln deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-11-07 07:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>(Adds details in paragraphs 2-5)</p><p>      Nov 6 (Reuters) - Avid Bioservices    said on Wednesday that it would be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in a deal valued at about $1.1 billion.</p><p>   GHO and Ampersand have offered $12.50 per share in cash, representing a premium of 13.8% to Avid's last closing price. </p><p>       The transaction is expected to close in the first quarter of 2025.</p><p>       \"In evaluating this transaction, our board considered a range of alternatives and determined that it provides our stockholders significant, immediate and certain cash value for their shares,\" Avid CEO Nick Green said. </p><p>       Upon completion of the transaction, Avid common stock will no longer be listed on any public stock exchange. The company will continue to operate under the Avid name and brand.</p><p>       Avid is a contract manufacturer that provides clinical and commercial manufacturing services to the biotechnology and biopharmaceutical industries. </p><p> (Reporting by Sneha S K in Bengaluru; Editing by Shailesh Kuber and Anil D'Silva)</p><p>((Sneha.SK@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2481964191","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481964191","pubTimestamp":1730935681,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"(Adds details in paragraphs 2-5)      Nov 6 (Reuters) - Avid Bioservices    said on Wednesday that it would be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in a dea","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CDMOP":"Avid Bioservices, Inc. 10.50% Series E Convertible Preferred"},"translate_title":"更新1-Avid Bioservices将被GHO和Ampersand以11亿美元的交易私有化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDMOP":1},"content_text":"(Adds details in paragraphs 2-5)      Nov 6 (Reuters) - Avid Bioservices    said on Wednesday that it would be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in a deal valued at about $1.1 billion.   GHO and Ampersand have offered $12.50 per share in cash, representing a premium of 13.8% to Avid's last closing price.        The transaction is expected to close in the first quarter of 2025.       \"In evaluating this transaction, our board considered a range of alternatives and determined that it provides our stockholders significant, immediate and certain cash value for their shares,\" Avid CEO Nick Green said.        Upon completion of the transaction, Avid common stock will no longer be listed on any public stock exchange. The company will continue to operate under the Avid name and brand.       Avid is a contract manufacturer that provides clinical and commercial manufacturing services to the biotechnology and biopharmaceutical industries.  (Reporting by Sneha S K in Bengaluru; Editing by Shailesh Kuber and Anil D'Silva)((Sneha.SK@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}